Table 1
The Patient's Clinical Course Following Immediate-release Pramipexole Treatment
| Follow-up (month) | Initial visit1 0 | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| IRLS score | 34 | 10 | 17 | 21 | 26 | 18 |
| Migraine frequency (/month) | 6 | 6 | 4 | 3 | 0 | 1 |
Table 2
Clinical Features of Patients with Migraines and RLS Who Received Immediate-release Pramipexole Treatment
| No | Age (years) | IRLS | RLS onset age (years) | Migraine onset age (years) | Migraine Characteristics | Morning Headache before P-IR Treatment | Migraine Frequency Before/After P-IR Treatment (months) | P-IR Daily Dose (mg)/Treatment Duration (months) | BDI-II | PSQI | ESS | Concomitant Medication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 22 | 26 | 6 | 6 | Pulsating and pressing | + | >15/>15 | 0.375/10 | 20 | 7 | 4 | Eletriptan 20 mg/as needed, naproxen 100 mg/as needed, domperidone 10 mg/as needed, brotizolam 0.25 mg/day, rabeprazole 10 mg/day |
| 21 | 27 | 31 | 25 | 15 | Pulsating | – | 12–14/12–14 | 0.5/16 | 42 | 13 | 16 | Sumatriptan 6 mg sc/as needed, zolmitriptan 2.5 mg/as needed, naproxen 100 mg/as needed |
| 31 | 27 | 20 | 27 | 17 | Pulsating | + | 15/15 | 0.125/9 | 18 | 7 | 10 | Eletriptan 20 mg/as needed, naproxen 100 mg/as needed, clonazepam 0.5 mg/day, amitriptyline 10 mg/day, topiramate 50 mg/day, omeprazole 10 mg/day, zolpidem 10 mg/day |
| 4 | 53 | 21 | 27 | 16 | Pulsating and pressing | – | >15/>15 | 0.375/30 | 5 | 5 | 4 | Clonazepam 1 mg/day,etizolam 0.5 mg/day, betahistine mesilate 6 mg/as needed, ibudilast 30 mg/day |
| 5 | 37 | 29 | 36 | 10 | Pressing | – | 10–14/10–14 | 0.125/29 | 5 | 10 | 8 | Eletriptan 20 mg/as needed, valproic acid 100 mg/day, topiramate 100 mg/day, rabeprazole 10 mg/day |
| 6 | 23 | 8 | 23 | 17 | Pulsating | – | 4/1 | 0.125/2 | 21 | 8 | 13 | Rizatriptan 10 mg/as needed |
| 71 | 57 | 22 | 56 | 30 | Tightening | + | 3–4/1 | 0.125/23 | 20 | 14 | 13 | Loxoprofen 60 mg/as needed, atorvastatin 10 mg/day, mecobalamin 1500 μg/day, amlodipine 2.5 mg/day |
| 8 | 52 | 19 | 57 | 30 | Pulsating | + | 15>/2–3 | 0.125/14 | 11 | 12 | 10 | Rizatriptan 10 mg/as needed, naproxen 100 mg/as needed, amitriptyline 10 mg/day |
| 91 | 20 | 29 | 20 | 13 | Pulsating and tightening | + | 15>/3–4 | 0.125/2 | 40 | 14 | 20 | Zolmitriptan 2.5 mg/as needed, loxoprofen 60 mg/as needed, betahistine mesilate 6 mg/as needed, amitriptyline 10 mg/day, clonazepam 0.5 mg/day, valproic acid 400 mg/day, omeprazole 10 mg/day, teprenone 150 mg/day |
| 10 | 35 | 34 | 7 | 20 | Pulsating | + | 6/1–2 | 0.125/5 | 20 | 13 | 15 | Rizatriptan 10 mg/as needed, aspirin 330 mg/as needed, domperidone 10 mg/as needed, sennoside 12 mg/day |
ESS, Epworth Sleepiness Scale; BDI-II, Beck Depression Inventory-II; IRLS, International Restless Legs Syndrome Study Group Rating Scale; PSQI, Pittsburgh Sleep Quality Index; RLS, Restless legs syndrome; P-IR, immediate-release pramipexole.
1 Pramipexole treatment began after the survey was performed between June and November 2010 from which the scores of BDI-II, PSQI and ESS of each patient was obtained.4